dual agonist glp 1 The glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Dual GLP-1/GIP receptor agonists mechanism

The study published in JAMA Psychiatry found that patients with alcohol use disorder (AUD) who were prescribed GLP-1 drugs, popularly known by their brand names Ozempic and Wegovy, had a significantly lower risk of hospitalization for alcohol-related issues.Background on Semaglutide and LiraglutideSemaglutide and liraglutide are medications b

Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.

The GLP-1 Receptor Agonist market size reached USD 15.25 Billion in 2024 and is expected to register a revenue CAGR of 21.7%

The global obesity treatment market is expanding at unprecedented speed, with sales of weight-loss medications forecast to rise dramatically over the next decade.